BRPI0715935A2 - a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores. - Google Patents

a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores.

Info

Publication number
BRPI0715935A2
BRPI0715935A2 BRPI0715935-8A2A BRPI0715935A BRPI0715935A2 BR PI0715935 A2 BRPI0715935 A2 BR PI0715935A2 BR PI0715935 A BRPI0715935 A BR PI0715935A BR PI0715935 A2 BRPI0715935 A2 BR PI0715935A2
Authority
BR
Brazil
Prior art keywords
beta
buffers
antibiotic composition
composition containing
lactam antibiotics
Prior art date
Application number
BRPI0715935-8A2A
Other languages
English (en)
Inventor
Hesheng Zhang
Original Assignee
Tianjin Hemay Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Bio Tech Co Ltd filed Critical Tianjin Hemay Bio Tech Co Ltd
Publication of BRPI0715935A2 publication Critical patent/BRPI0715935A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A COMPOSIÇçO ANTIBIàTICA CONTENDO OS ANTIBIàTICOS BETA-LACTÂMICOS E AMORTECEDORES. A composição dos antibióticos que compreende pelo menos um dos antibióticos beta-lactâmicos e amortecedores, ainda compreendedo pelo menos um aos antibióticos aminoglicosídicos, na solução para controlar a infecção microbiana em um recipiente.
BRPI0715935-8A2A 2006-08-25 2007-08-14 a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores. BRPI0715935A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006100154382A CN101129382B (zh) 2006-08-25 2006-08-25 含β-内酰胺类抗生素和缓冲组分的抗生素复方
PCT/CN2007/002441 WO2008025228A1 (en) 2006-08-25 2007-08-14 The antibiotics composition comprising beta-lactam antibiotics and buffers

Publications (1)

Publication Number Publication Date
BRPI0715935A2 true BRPI0715935A2 (pt) 2013-09-17

Family

ID=39126892

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715935-8A2A BRPI0715935A2 (pt) 2006-08-25 2007-08-14 a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores.

Country Status (11)

Country Link
US (1) US20090156518A1 (pt)
EP (2) EP2500023A1 (pt)
JP (1) JP5371755B2 (pt)
KR (1) KR20090042995A (pt)
CN (1) CN101129382B (pt)
AU (1) AU2007291767B2 (pt)
BR (1) BRPI0715935A2 (pt)
CA (1) CA2661764A1 (pt)
DK (1) DK2062582T3 (pt)
RU (1) RU2459625C2 (pt)
WO (1) WO2008025228A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101710A1 (en) * 2010-02-16 2011-08-25 Wockhardt Research Centre Efflux pump inhibitors
WO2009147635A1 (en) * 2008-06-05 2009-12-10 Pfeinsmith S.A. (Pty) Ltd Fulvic acid and antibiotic combination
KR20110058887A (ko) * 2008-09-18 2011-06-01 마누 차우드하리 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형
CN101590061B (zh) * 2009-04-14 2010-09-29 深圳立健药业有限公司 一种头孢替坦二钠的药物组合物
CN101537009B (zh) * 2009-04-30 2010-09-15 海口奇力制药股份有限公司 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺
CN101647800B (zh) * 2009-08-10 2011-08-31 北京联木医药技术发展有限公司 一种头孢呋辛酸的组合物
CN101940573B (zh) * 2010-01-21 2013-03-20 深圳市新泰医药有限公司 一种头孢孟多酯钠和舒巴坦钠的组合物及其配比
CN101940572A (zh) * 2010-01-21 2011-01-12 深圳市新泰医药有限公司 一种头孢孟多酯钠和他唑巴坦钠的组合物及其配比
CN102058583B (zh) * 2010-12-14 2013-04-03 重庆福安药业(集团)股份有限公司 一种替卡西林钠克拉维酸钾冻干粉及其制剂和制备方法
CN102652750B (zh) * 2011-03-04 2014-04-02 珠海联邦制药股份有限公司 一种含头孢呋辛的药物组合物及其制剂和制备方法
CN102349897B (zh) * 2011-07-22 2012-12-26 深圳市新泰医药有限公司 一种美罗培南钠/他唑巴坦钠药物组合物
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN105026407B (zh) 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US20160310472A1 (en) * 2013-10-22 2016-10-27 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and imipenem
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN104382899B (zh) * 2014-11-20 2021-02-12 重庆福安药业(集团)股份有限公司 一种美洛西林钠舒巴坦钠的复方药物组合物
CN105085543A (zh) * 2015-09-10 2015-11-25 青岛蓝盛洋医药生物科技有限责任公司 一种抗菌药物舒巴坦钠组合物
CN105456268B (zh) * 2015-12-28 2018-09-25 重庆福安药业(集团)股份有限公司 哌拉西林钠他唑巴坦钠的复方药物组合物及其制备方法
CN105663037A (zh) * 2016-01-27 2016-06-15 成都乾坤动物药业有限公司 一种阿莫西林溶液剂及其制备方法和用途
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
MA47743A (fr) 2017-03-06 2020-01-15 Venatorx Pharmaceuticals Inc Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
CN108802206A (zh) * 2017-05-05 2018-11-13 江苏灵豹药业股份有限公司 一种同时测定注射用头孢噻肟钠他唑巴坦钠中主要成分和主要杂质的含量的方法
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) * 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
CN113382713A (zh) 2018-11-29 2021-09-10 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物及其用途
CN110025584A (zh) * 2019-05-06 2019-07-19 哈尔滨誉衡制药有限公司 一种头孢米诺钠注射制剂的制备方法
CN110003240A (zh) * 2019-05-06 2019-07-12 哈尔滨誉衡药业股份有限公司 一种头孢米诺钠原料及其制备方法和制剂
CN110507619B (zh) * 2019-08-19 2021-12-03 湖北美林药业有限公司 注射用头孢哌酮钠及其制备方法
CN111034711B (zh) * 2019-12-19 2022-04-05 海南一龄医疗产业发展有限公司 高效清除细胞培养过程中微生物污染的组合物及方法
WO2021183590A1 (en) * 2020-03-10 2021-09-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Antiseptic-antibiotic gumbos effective against gram-negative pathogens
CN116942617A (zh) * 2023-08-28 2023-10-27 重庆士立德医药科技有限公司 一种苯唑西林钠组合物及其制备方法
CN118852205A (zh) * 2024-07-19 2024-10-29 天津大学 头孢美唑钠水合物晶体及其制备方法、组合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759951A (en) * 1953-04-10 1956-10-24 Pfizer & Co C Improvements in or relating to penicillin compositions
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
DK1468697T3 (da) * 2003-04-14 2008-04-14 Wyeth Corp Sammensætninger indeholdende piperacillin og tazobactam, der er anvendelige til injektion
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
CN1565457A (zh) * 2003-06-21 2005-01-19 张哲峰 一种抑制β－内酰胺酶的抗菌组合药物
CN1485035A (zh) * 2003-08-12 2004-03-31 宇 周 一种美洛西林的抗菌组合药物
CN1259917C (zh) * 2004-06-18 2006-06-21 余安国 供注射用的头孢克肟药物复合物
EP1799209A1 (en) * 2004-10-14 2007-06-27 Wyeth Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent
ATE476981T1 (de) * 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
CN100356921C (zh) * 2004-12-24 2007-12-26 邢为藩 一种硫酸头孢匹罗组合物及其制备方法
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis

Also Published As

Publication number Publication date
CA2661764A1 (en) 2008-03-06
KR20090042995A (ko) 2009-05-04
AU2007291767B2 (en) 2013-05-09
RU2459625C2 (ru) 2012-08-27
EP2062582A4 (en) 2009-11-25
JP5371755B2 (ja) 2013-12-18
CN101129382A (zh) 2008-02-27
RU2009105844A (ru) 2010-09-27
CN101129382B (zh) 2013-12-25
DK2062582T3 (da) 2013-07-15
US20090156518A1 (en) 2009-06-18
EP2062582B1 (en) 2013-04-17
WO2008025228A1 (en) 2008-03-06
AU2007291767A1 (en) 2008-03-06
EP2062582A1 (en) 2009-05-27
JP2010501494A (ja) 2010-01-21
EP2500023A1 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
BRPI0715935A2 (pt) a composiÇço antibiàtica contendo os antibiàticos beta-lactÂmicos e amortecedores.
BRPI0715936A2 (pt) a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos.
CL2011000783A1 (es) Combinacion sinergica de un compuesto heterociclico nitrogenado de formula i antibacteriano con otro compuesto antibacteriano; medicamento; composicion farmaceutica; util para tratar infecciones bacterianas.
MX338505B (es) Combinaciones utiles de antibioticos de monobactama con inhibidores de beta-lactamasa.
ECSP10010345A (es) Inhibidores de beta-lactamasa
TW200744632A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
CL2012002382A1 (es) Combinaciones fungicidas que consisten de tebuconazol, axistrobina y fludioxonil, y uno o más auxiliares de formulación habituales (div. sol. 1791-07).
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
BRPI0712171A8 (pt) Método para formatar um gráfico e sistema para modificar um gráfico
ATE493037T1 (de) Mykotoxin reduzierende zusammensetzung
BRPI1013142A2 (pt) Artigos absorventes compreendendo um sistema para controle de odores
WO2008152447A3 (en) Staphylococcus aureus specific anti-infectives
CL2008003309A1 (es) Compuestos derivados de citosina (=4-amino-pirimidin-2-ona) sustituida, moduladores de quinasas de punto de control del ciclo celular; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento o la disminucion de la progresion del cancer.
CL2011000209A1 (es) Composicion biocida que comprende ciprodinil y piribencarb; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n° 2602-06).
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0814641A2 (pt) composição farmacêutica, substrato compreendendo uma composição farmacêutica e uso de uma composição farmacêutica.
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
BRPI0716342A2 (pt) ''composição para controlar o crescimento de microorganismos,método para controlar o crescimento de pelo menos um microorganismo e método para evitar a detrioração de um produto''
TW200734344A (en) Antibacterial agents
BRPI0600050A (pt) revestimento antibiótico de implantes
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
CL2007003693A1 (es) Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
BRPI0514723A (pt) composições contendo componentes de agonista alfa-2-adrenérgico
EP2036917A4 (en) NEW AMINOGLYCOSIDANTIBIOTICUM
WO2007060649A3 (en) Diagnostic composition and article for monitoring intravaginal infections

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.